Pennsylvania
Department of Human Services

Office of Medical Assistance Programs
Bureau of Fee-for-Service Programs, Pharmacy Division
Phone 1-800-537-8862 Fax 1-866-327-0191

LIPOTROPICS, OTHER PRIOR AUTHORIZATION FORM *(form effective 7/6/2026)*

Prior authorization guidelines **Lipotropics, Other** and **Quantity Limits/Daily Dose Limits** are available on the DHS Pharmacy Services website at https://www.pa.gov/agencies/dhs/resources/for-providers/ma-for-providers/pharmacy-services.

☐New request ☐Renewal request	Total pages: _____	Prescriber name:	
Name of office contact:		Specialty:	
Contact's phone number:		NPI:	State license #:
LTC facility contact/phone:		Street address:	
Beneficiary name:		City/state/zip:	
Beneficiary ID#:	DOB:	Phone:	Fax:

CLINICAL INFORMATION

Drug requested:	Strength:	Dosage form:	
Dose/directions:		Quantity:	Refills:
Diagnosis *(submit documentation)*:		Dx code (*required*):	

Complete all sections that apply to the beneficiary and this request.
Check all that apply and submit documentation for each item.

INITIAL requests

1. For treatment of ANY LIPID DISORDER:

☐Has results of a lipid profile within the past 3 months

2. For a PCSK9 INHIBITOR (eg, Leqvio, Praluent, Repatha), NEXLETOL (bempedoic acid), or NEXLIZET (bempedoic acid/ezetimibe):

☐Has at least ONE of the following **diagnoses**:
- ☐A history of clinical atherosclerotic cardiovascular disease
- ☐Familial hypercholesterolemia
- ☐Severe hypercholesterolemia (baseline LDL-C ≥190 mg/dL)

☐ONE of the following related to history of **statin** use:
- ☐Failed to achieve goal non-HDL-C, LDL-C, percentage reduction of LDL-C, or apoB with maximally tolerated dose of a high-intensity statin (eg, atorvastatin, rosuvastatin) for at least 3 consecutive months
- ☐Is unable to tolerate high-intensity statins AND:
  - ☐Has a temporally related intolerance to a high-intensity statin
  - ☐Tried and failed or has an intolerance to the lowest FDA-approved daily dose or alternate-day dosing of any statin for at least 3 months
  - ☐Modifiable comorbid conditions that may enhance statin intolerance were ruled out and/or addressed by the prescriber (eg,

hypothyroidism, vitamin D deficiency, etc.)
- ☐ All possible drug interactions with statins were addressed (eg, dose decrease or discontinuation of the interacting drug, change to an alternative statin that has a lower incidence of drug interactions)

☐ Has a contraindication to statins

☐ ONE of the following related to history of **ezetimibe** use:
- ☐ Failed to achieve goal LDL-C or percentage reduction of LDL-C with ezetimibe in combination with maximally tolerated dose of the highest-tolerated intensity statin (eg, atorvastatin, rosuvastatin) for at least 3 consecutive months
- ☐ Has a contraindication or an intolerance to ezetimibe
- ☐ **For a PCSK9 INHIBITOR,** has an LDL-C that is >25% above goal LDL-C while adherent to treatment with the maximally tolerated dose of the highest-tolerated intensity statin for at least 3 consecutive months

☐ ONE of the following:
- ☐ For a diagnosis of homozygous familial hypercholesterolemia, is prescribed the requested drug in addition to other standard lipid-lowering therapies
- ☐ For all other diagnoses, is prescribed the requested drug in addition to the maximally tolerated dose of the highest-tolerated intensity statin (if clinically appropriate)

☐ **For a NON-PREFERRED PCSK9 INHIBITOR:**
- ☐ Tried and failed a preferred PCSK9 inhibitor or has a contraindication or an intolerance to the preferred PCSK9 inhibitors approved or medically accepted for the treatment of the beneficiary's diagnosis (*Refer to https://papdl.com/preferred-drug-list for a list of preferred and non-preferred drugs in this class.)*

☐ **For NEXLETOL (bempedoic acid) or NEXLIZET (bempedoic acid/ezetimibe):**
- ☐ If currently taking simvastatin or pravastatin, will not be using Nexletol/Nexlizet concomitantly with simvastatin at a dose of >20 mg daily or pravastatin at a dose of >40 mg daily

3. For EVKEEZA (evinacumab) or JUXTAPID (lomitapide):

☐ Is prescribed the requested medication by or in consultation with a cardiologist, endocrinologist, or other provider specializing in lipid disorders

☐ ONE of the following:
- ☐ Tried and failed or has a contraindication or an intolerance to PCSK9 inhibitors
- ☐ Has results of genetic testing that are positive for mutations associated with lack of response to PCSK9 inhibitors

☐ Is prescribed the requested medication in addition to other standard lipid-lowering therapies

4. For VASECPA (icosapent ethyl):

☐ ONE of the following:
- ☐ Has a history of clinical atherosclerotic cardiovascular disease (ASCVD)
- ☐ BOTH of the following:
  - ☐ Has diabetes mellitus
  - ☐ Has at least one additional ASCVD risk factor *(check all that apply)*:
    - ☐ age ≥50 years
    - ☐ retinopathy
    - ☐ micro- or macroalbuminuria
    - ☐ hs-CRP >3.0 mg/L
    - ☐ ABI <0.9
    - ☐ HDL-C ≤40 mg/dL for males or ≤50 mg/dL for females
    - ☐ current smoker or stopped smoking within 3 months
    - ☐ hypertension or taking antihypertensive medication
    - ☐ CrCl >30 mL/min and <60 mL/min
    - ☐ other: _____

- ☐ Tried and failed or has a contraindication or an intolerance to a preferred fibric acid derivative Lipotropics, Other approved or medically accepted for the treatment of the beneficiary's diagnosis (*Refer to https://papdl.com/preferred-drug-list for a list of preferred and non-preferred drugs in this class.)*

☐ Has fasting triglycerides ≥150 mg/dL

☐ ONE of the following:

☐ Tried and failed maximally tolerated doses of a statin for at least 3 months
☐ Has a history of statin intolerance after modifiable risk factors have been addressed (eg, drug interactions, hypothyroidism, vitamin D deficiency, etc.)
☐ Has a contraindication to statins

5. For an APOC-III-DIRECTED Lipotropics, Other (eg, Redemplo, Tryngolza):

☐ Is prescribed the requested medication by or in consultation with a cardiologist, endocrinologist, gastroenterologist, or other provider specializing in lipid disorders

☐ **For a diagnosis of familial chylomicronemia syndrome (FCS),** BOTH of the following:
- ☐ Untreated fasting triglycerides ≤880 mg/dL
- ☐ ONE of the following:
  - ☐ Results of genetic testing showing biallelic pathogenic variations in FCS-causing genes
  - ☐ A North American FCS score ≥60 (i.e., definite FCS)
  - ☐ BOTH of the following:
    - ☐ A North American FCS score ≥45 and <60 (i.e., likely FCS)
    - ☐ An FCS score (Moulin score) ≥10 (i.e., FCS very likely)

☐ **For a diagnosis other than FCS:**
- ☐ Has a diagnosis that is confirmed according to applicable consensus guidelines
- ☐ Tried and failed or has a contraindication or intolerance to first-line therapy(ies) if applicable according to consensus treatment guidelines

☐ **For TRYNGOLZA (olezarsen):**
- ☐ Tried and failed or has a contraindication or an intolerance to Redemplo (plozasiran) if Redemplo is approved or medically accepted for the beneficiary's diagnosis

6. For ALL OTHER NON-PREFERRED Lipotropics, Other:

☐ Tried and failed or has a contraindication or an intolerance to the preferred Lipotropics, Other approved or medically accepted for the beneficiary's diagnosis *(Refer to https://papdl.com/preferred-drug-list for a list of preferred and non-preferred drugs in this class.)*

RENEWAL requests

1. For ALL diagnoses:

☐ Experienced a positive clinical response demonstrated by lab test results, if appropriate for the diagnosis, since starting the requested medication (e.g., decreased LDL-C, decreased triglycerides, etc.)

2. For a PCSK9 INHIBITOR (eg, Leqvio, Praluent, Repatha):

☐ For a diagnosis of homozygous familial hypercholesterolemia, is using the requested PCKS9 inhibitor in addition to other standard lipid-lowering treatments
☐ For all other diagnoses, is using the requested PCSK9 inhibitor in addition to the maximally tolerated dose of the highest-tolerated intensity statin (if clinically appropriate)

☐ **For a NON-PREFERRED PCSK9 INHIBITOR:**
- ☐ Tried and failed a preferred PCSK9 inhibitor or has a contraindication or an intolerance to the preferred PCSK9 inhibitors approved or medically accepted for the treatment of the beneficiary's diagnosis (*Refer to https://papdl.com/preferred-drug-list for a list of preferred and non-preferred drugs in this class.)*

3. For NEXLETOL (bempedoic acid) or NEXLIZET (bempedoic acid/ezetimibe):

☐ Is using the requested medication in addition to the maximally tolerated dose of the highest-tolerated intensity statin (if clinically appropriate)

☐ If currently taking simvastatin or pravastatin, will not be using Nexletol/Nexlizet concomitantly with simvastatin at a dose of >20 mg daily or pravastatin at a dose of >40 mg daily

4. For EVKEEZA (evinacumab) or JUXTAPID (lomitapide):

☐ Is prescribed the requested medication by or in consultation with a cardiologist, endocrinologist, or other provider specializing in lipid disorders

☐ Is using the requested medication in addition to other standard lipid-lowering treatments

5. For an APOC-III-DIRECTED Lipotropics, Other (eg, Redemplo, Tryngolza):

☐ Is prescribed the requested medication by or in consultation with a cardiologist, endocrinologist, gastroenterologist, or other provider specializing in lipid disorders

☐ **For TRYNGOLZA (olezarsen):**

☐ Tried and failed or has a contraindication or an intolerance to Redemplo (plozasiran) if Redemplo is approved or medically accepted for the beneficiary's diagnosis

6. For ALL OTHER NON-PREFERRED Lipotropics, Other:

☐ Tried and failed or has a contraindication or an intolerance to the preferred Lipotropics, Other approved or medically accepted for the beneficiary's diagnosis *(Refer to https://papdl.com/preferred-drug-list for a list of preferred and non-preferred drugs in this class.)*

PLEASE FAX COMPLETED FORM WITH REQUIRED CLINICAL DOCUMENTATION TO DHS – PHARMACY DIVISION

Prescriber Signature:	**Date**:

Confidentiality Notice: The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.